arrow
T

Tara L. Lin

University of Kansas Medical Center
H指数:33
被引数:7,253

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA

信号突变抵消了新诊断急性髓系白血病老年患者接受VEN/HMA治疗时NPM1突变的有利影响

2026-07-020
OAAI
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia

Ziftomenib联合venetoclax和azacitidine在复发/难治性NPM1突变急性髓系白血病中的应用

Blood
IF23.1
2026-06-030
PRE
CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial

在关键性随机试验中,CPX-351选择性地使AML和脊髓发育不良相关突变患者受益

2026-02-040
OAAI
Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium

CPX-351在AML-MR中的真实世界分析:MARROW联盟的多中心研究

2025-12-010
OA
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy

低剂量阿糖胞苷和维奈克拉在不符合强化疗条件的急性髓系白血病患者中的风险分层

2025-11-240
OAAI
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia

MICA/MICB的下调增强了NKG2DL CAR T细胞在复发或难治性急性髓系白血病或骨髓异常增生性肿瘤患者中的细胞持久性和临床活性。

Leukemia
IF13.4
2025-09-150
PRE
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial

新诊断急性髓系白血病60岁及以上患者的分子特征分析:Beat AML临床试验报告

2025-04-030
OA
IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

IDH2突变与接受低强度治疗的新诊断急性髓系白血病老年患者的良好预后相关。

BLOOD
IF23.1
2024-11-051
PRE
Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

新诊断、老年急性髓系白血病患者在Venetoclax/阿扎胞苷时代的Beat AML主试验中的结局与生存情况

BLOOD
IF23.1
2024-11-050
PRE
A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax plus Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

一项随机Ⅱ期临床试验,比较28天(A组)与14天(B组)方案下Venetoclax联合Azacitidine治疗初诊急性髓系白血病患者(≥60岁)的效果。

BLOOD
IF23.1
2024-11-050
PRE
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy

Beat-aml 2024 ELN-对新诊断AML的老年人进行低强度治疗的风险分层

2024-10-102
OAAI